BTIG analyst Robert Hazlett names Syndax (SNDX) as his BTIG Top Pick for first half of 2023, replacing CTI Biopharma (CTIC) on that list. There is material potential for Syndax’s menin inhibitor Revumenib in acute leukemias, and for Axatilimab, its novel CSF-1R antibody in chronic Graft vs. Host Disease and possibly other settings, the analyst tells investors in a research note. Hazlett has a Buy rating and a $34 price target on the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNDX:
- Syndax initiated with an Overweight at JPMorgan
- Barclays views GSK acquisition interest as positive for oncology stocks
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Syndax price target raised to $33 from $31 at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today